$2.45T
Total marketcap
$77.07B
Total volume
BTC 50.63%     ETH 14.88%
Dominance

PharmaSGP Holding SE PSG.F Stock

22.4 EUR {{ price }} -0.884959% {{change_pct}}%
COUNTRY
Germany
Exchange
Frankfurt
Market Cap
268.58M EUR
LOW - HIGH [24H]
22.4 - 22.4 EUR
VOLUME [24H]
90 EUR
{{ volume }}
P/E Ratio
17.92
Earnings per share
1.25 EUR

PharmaSGP Holding SE Price Chart

PharmaSGP Holding SE PSG.F Financial and Trading Overview

PharmaSGP Holding SE stock price 22.4 EUR
Previous Close 28.2 EUR
Open 28 EUR
Bid 28.5 EUR x N/A
Ask 0 EUR x N/A
Day's Range 28.1 - 28.1 EUR
52 Week Range 22.5 - 29 EUR
Volume 40 EUR
Avg. Volume 29 EUR
Market Cap 337.2M EUR
Beta (5Y Monthly) -0.113761
PE Ratio (TTM) 25.545454
EPS (TTM) 1.25 EUR
Forward Dividend & Yield 0.49 (1.70%)
Ex-Dividend Date June 29, 2023
1y Target Est N/A

PSG.F Valuation Measures

Enterprise Value 377.76M EUR
Trailing P/E 25.545454
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 3.7774317
Price/Book (mrq) 9.982238
Enterprise Value/Revenue 4.232
Enterprise Value/EBITDA 13.266

Trading Information

PharmaSGP Holding SE Stock Price History

Beta (5Y Monthly) -0.113761
52-Week Change 23.24%
S&P500 52-Week Change 20.43%
52 Week High 29 EUR
52 Week Low 22.5 EUR
50-Day Moving Average 27.66 EUR
200-Day Moving Average 25.89 EUR

PSG.F Share Statistics

Avg. Volume (3 month) 29 EUR
Avg. Daily Volume (10-Days) 26 EUR
Shares Outstanding 12M
Float 2.36M
Short Ratio N/A
% Held by Insiders 80.10%
% Held by Institutions 11.48%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0.49
Trailing Annual Dividend Yield 1.73%
5 Year Average Dividend Yield N/A
Payout Ratio 0.4091
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 14.69%
Operating Margin (ttm) 22.19%
Gross Margin 90.03%
EBITDA Margin 31.90%

Management Effectiveness

Return on Assets (ttm) 9.79%
Return on Equity (ttm) 45.82%

Income Statement

Revenue (ttm) 89.27M EUR
Revenue Per Share (ttm) 7.46 EUR
Quarterly Revenue Growth (yoy) 16.69%
Gross Profit (ttm) 76.79M EUR
EBITDA 28.48M EUR
Net Income Avi to Common (ttm) 13.12M EUR
Diluted EPS (ttm) 1.1
Quarterly Earnings Growth (yoy) 69.19%

Balance Sheet

Total Cash (mrq) 37.31M EUR
Total Cash Per Share (mrq) 3.15 EUR
Total Debt (mrq) 81.97M EUR
Total Debt/Equity (mrq) 245.59 EUR
Current Ratio (mrq) 2.338
Book Value Per Share (mrq) 2.815

Cash Flow Statement

Operating Cash Flow (ttm) 28.14M EUR
Levered Free Cash Flow (ttm) 21.3M EUR

Profile of PharmaSGP Holding SE

Country Germany
State N/A
City Gräfelfing
Address Lochhamer Schlag 21
ZIP 82166
Phone 49 89 85 89 639
Website https://pharmasgp.com
Industry Drug Manufacturers-Specialty & Generic
Sector(s) Healthcare
Full Time Employees 79

PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for treatment of hair loss; Dorisol, a pain relies tablet; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten, for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness and mood swings; Deruba, a cream for skin redness; Lentisol prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.

Q&A For PharmaSGP Holding SE Stock

What is a current PSG.F stock price?

PharmaSGP Holding SE PSG.F stock price today per share is 22.4 EUR.

How to purchase PharmaSGP Holding SE stock?

You can buy PSG.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for PharmaSGP Holding SE?

The stock symbol or ticker of PharmaSGP Holding SE is PSG.F.

Which industry does the PharmaSGP Holding SE company belong to?

The PharmaSGP Holding SE industry is Drug Manufacturers-Specialty & Generic.

How many shares does PharmaSGP Holding SE have in circulation?

The max supply of PharmaSGP Holding SE shares is 11.99M.

What is PharmaSGP Holding SE Price to Earnings Ratio (PE Ratio)?

PharmaSGP Holding SE PE Ratio is 17.92000000 now.

What was PharmaSGP Holding SE earnings per share over the trailing 12 months (TTM)?

PharmaSGP Holding SE EPS is 1.25 EUR over the trailing 12 months.

Which sector does the PharmaSGP Holding SE company belong to?

The PharmaSGP Holding SE sector is Healthcare.